Search

Breast cancer is the most common malignant tumor among women in the world. According to data from the World Health Organization, in 2020, there were approximately 2.26 million new breast cancer cases worldwide, accounting for 11.7% of all new cancer cases. In recent years, with the rapid development of molecular biology and gene detection technology, the research on advanced breast cancer continues to deepen, and the treatment methods are constantly enriched. Gene targeted therapy significantly prolongs the survival period of patients with advanced breast cancer, which is of great significance for molecular pathological diagnosis, targeted drug selection and treatment mode optimization of patients with advanced breast cancer. Based on the development of literature and clinical research, the consensus expert committee formulated the "Expert consensus on clinical application of next-generation sequencing in advanced breast cancer (2024 edition)". Compared with the "Chinese Expert Consensus on Hot Issues of Gene Testing for Advanced breast cancer (2021)", the 2024 consensus adopts new evidence-based medical evidence, aiming to provide more comprehensive gene testing information for patients with advanced breast cancer, so as to develop more accurate treatment strategies. [ABSTRACT FROM AUTHOR]

Breast cancer ranks as the most common female malignancy worldwide. Data from GLOBOCAN 2020 showed that breast cancer surpassed lung cancer and become the leading malignancy globally which was a serious threat to women's health. Different from Caucasian, there i a lower prevalence of breast cancer in Chinese women. However, the age-standardized incidence rate of breast cancer in China has reached to 39.1 per 100,000 in 2020, with 416,000 new cases, accounting for 18.4% of global breast cancer burden, due to multiple factors such as lifestyle and dietary habits changes in recent years. The treatment and prevention of breast cancer are becoming increasingly a tuff task. In addition, triple-negative breast cancer (TNBC) is a subtype with higher malignancy and worse prognosis. Due to lack of specific therapeutic targets, less treatment progress has been made in recent years. There is even less progress in the therapy of advanced TNBC, but huge unmet needs exist for further therapeutic optimization. Echoing advocacy from The Society of Breast Cancer China Anti-Cancer Association; International Medical Exchange Society, China Anti-Cancer Association; Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association, top experts from multidisciplinary departments of breast cancer in China have consensus on this "Guidelines for clinical diagnosis and treatment of advanced triple-negative breast cancer in China (2024 edition)" according to the latest evidence based updates. We hope this pater can guide or optimize the precise therapeutic decision-making for advanced triple-negative breast cancer in China. [ABSTRACT FROM AUTHOR]

Antibody-drug conjugates (ADCs) are drugs that combine monoclonal antibody drugs targeting specific antigens and small molecule cytotoxic drugs through linker molecules. ADCs combine the advantages of high specificity targeting and potent killing effects, achieving precise and efficient targeting of cancer cells. Nowadays, ADCs are one of the hotspots in cancer drug development. Human epidermal growth factor receptor 2 (HER-2) is a known oncogene that can drive the occurrence and development of various types of tumors. HER-2 is also an important tumor target for ADCs approved for solid tumors. Anti-HER-2 ADCs can not only be used to treat HER-2-positive tumors but also effectively target HER-2-low tumors. The emergence of ADCs has broken the traditional classification of HER-2 in tumors, bringing significant treatment breakthroughs for HER-2-low tumors. Anti-HER-2 ADCs are widely used in the treatment of solid tumors and have substantial evidence for HER-2-low tumors. This article presents the progress of various anti-HER-2 ADCs in HER-2-low tumors including breast cancer, gastrointestinal malignancies, urothelial carcinoma, lung cancer. And this article summarizes the current status of preclinical studies, clinical studies, and safety of anti-HER-2 ADCs in order to provide reference for the clinical use of HER-2-low tumors. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Breast cancer is the most common malignant tumor in women around the world, and it is also a common cause of death in female patients with malignant tumors in China, which seriously harms women′s health. At present, with the application of comprehensive treatment approaches, breast cancer has become one of the most effective solid tumors. Platinum drugs are widely used in malignant tumors, and they are also commonly used as effective chemotherapeutic drugs for breast cancer. To regulate the application of platinum drugs in breast cancer, the experts from Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association, discuss and approve the "Guidelines for clinical application of platinum drugs in breast cancer (2023 edition)" . This guideline is developed from the "Expert consensus on the clinical application of platinums in advanced breast cancer (2020 version)", which is updated from the latest evidence based on breast cancer at home and abroad, for platinum drugs in breast cancer clinical use, application scheme, efficacy analysis and treatment of adverse effects. This guideline aims to guide clinicians to use drugs rationally, and to further standardize the diagnosis and treatment. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Breast cancer is the most common malignant tumor in women, of which the majority is early breast cancer (EBC). The strategy of postoperative adjuvant treatment relies mainly on the clinicopathologic characteristics of patients, but there are certain deficiencies if only depending on it to assess treatment benefits and disease prognosis. Multigene testing tools can evaluate the prognosis and predict therapeutic effects of breast cancer patients to guide the clinical decision-making on whether to use adjuvant chemotherapy, radiotherapy, and endocrine therapy by detecting the expression levels of specific genes. The consensus-writing expert group, based on the characteristics, validation results, and accessibility of the multigene testing tools and combined with clinical practice, described the result interpretation and clinical application of OncotypeDx® (21-gene), Mammaprint® (70-gene), RecurIndex® (28-gene), EndoPredict® (12-gene), and Breast Cancer Index® (BCI, 7-gene) for hormone receptor-positive and human epidermal growth factor receptor 2-negative EBC. The development and validation process of each tool was also briefly introduced. It is expected that the consensus will help guide and standardize the clinical use of multigene testing tools and further improve the level of precise treatment for EBC. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Breast cancer is the most common malignant tumor of women, which seriously threatens women's health. Albumin-bound paclitaxel is the basic chemotherapy drug for breast cancer treatment. We can promote reasonable clinical medication and improve patients' quality of life by standardizing chemotherapy plans, rationally optimizing treatment strategy and managing adverse reactions of albumin-bound paclitaxel. In order to standardize the clinical application of albumin-bound paclitaxel in breast cancer, Chinese Medical Doctor Association Oncologist Branch Breast Cancer Group and International Medical Exchange Branch of China Anti-Cancer Association consulted guidelines and the latest evidence-based evidences and formulated Chinese expert consensus of albumin-bound paclitaxel in the treatment of breast cancer to provide reference for clinical diagnosis and treatment of breast cancer. The consensus mainly introduces the clinical application strategies and evidence-based evidences of albumin-bound paclitaxel in advanced therapy, neoadjuvant therapy and adjuvant therapy of breast cancer. Among them, the regimens containing albumin-bound paclitaxel are the better recommended regimens for preoperative neoadjuvant and advanced rescue therapy of breast cancer. However, there is little evidence in adjuvant therapy, so it is recommended to use albumin-bound paclitaxel cautiously. We also invited breast cancer clinical experts to vote on some controversial issues, including but not limited to the usage and dosage of albumin-bound paclitaxel, combined medication and management of peripheral neuropathy, and formed consensus recommendations for the reference of breast cancer clinical workers. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The treatment of breast cancer with low expression of human epidermal growth factor receptor 2 ( HER-2) has become a focused area in recent years. With the proved therapeutic effect of antibody-drug conjugate on breast cancer patients with HER-2 low expression, HER-2-low expression may become a new subtype for targeted therapies of breast cancer. Standardized diagnosis and treatment are the foundation to guarantee efficacy. In order to improve the standardization of clinical diagnosis and treatment of HER-2-low breast cancer, the Consensus Expert Committee has summarized the latest domestic and global clinical data and the key relevant publications in recent years. We have combined them with clinical experience of pathologists and oncologists, had a deep discussion within the committee, and developed the consensus. We believe this consensus could help clinicians improve the understanding about HER-2-low breast cancer, promote the accuracy of decision-making and achieve the ultimate goal of prolonging the overall survival and improving the quality of life of patients. [ABSTRACT FROM AUTHOR]

TNBC is a special type of breast cancer with strong aggressiveness and poor prognosis. Chemotherapy is still the main treatment for TNBC, due to poor efficacy of endocrine therapy and targeted therapy. However, TNBC is a kind of heterogeneous disease, so it is urgent to study the precise molecular types and explore new precision treatment. This paper will summarize the results of clinical trials and analyze treatment strategies for TNBC, including surgical treatment, radiotherapy, chemotherapy, targeted therapy and immunotherapy, in order to provide evidence for clinical management. [ABSTRACT FROM AUTHOR]

Copyright of Cancer Research on Prevention & Treatment is the property of Cancer Research on Prevention & Treatment Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Breast cancer is the most common cancer in the world, and 5-year survival rate of metastatic breast cancer is about 20%. The treatment of metastatic breast cancer is mainly chemotherapy, endocrine therapy and targeted therapy. However, after multiline treatment, patients with MBC especially the triple negative breast cancer face the problem of drug resistance. Tumor angiogenesis theory suggests that blocking angiogenesis can inhibit tumor growth and migration. Based on this, angiogenesis treatment strategy is proposed. Antiangiogenic drugs mainly include biological macromolecular drugs targeting vascular endothelial growth factor ( VEGF) or vascular endothelial growth factor receptor ( VEGFR ) and small molecule VEGFR inhibitors. Angiogenesis is known to play a key role in the growth and metastasis of breast cancer. Therefore, anti-angiogenetic therapy has potential in metastatic breast cancer patients. Since the approval of tumor drug indications by NPMA in China is often later than the release of the latest research data, the National Health Commission issued " the guiding principles for the clinical application of new antitumor drugs" in 2020. The principle pointed out that under special circumstances such as the absence of better treatment, medical institutions should manage the usage of drugs that are not clearly defined in the instructions but have evidence-based data. Based on the latest research progress in breast cancer, the consensus writing expert group collated published reports, international academic conferences, conducted analysis, discussion and summary, collected data on the use of small molecule anti-vascular targeting drugs for advanced breast cancer, and formulated " expert consensus on the application of small molecule anti-angiogenic drugs in the treatment of advanced breast cancer". For clinicians' reference only. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Advanced breast cancer is a complicated disease with poor prognosis, which is difficult for salvage treatment. Although advanced breast cancer is difficult to cure at present, we can improve the life quality and prolong survival time of patients by applying optimized treatment. In recent years, with the rapid development of molecular biology and gene testing technology, studies on advanced breast cancer continue to deepen. Gene targeted therapy significantly extends the survival time of patients with advanced breast cancer. Gene testing is one of the important means for molecular typing, genetic diagnosis, therapeutic monitoring, drug resistance, and treatment choice of breast cancer, which is of great significance for the selection of targeted drugs and the management plan. In this consensus, the Expert Committee summarized ten hot issues of gene testing for advanced breast cancer and discussed the applicable population, clinical significance, and the application of molecular markers circulating tumor DNA (ctDNA), whole exome sequencing (WES) in different molecular types, and the standardization of next generation sequencing (NGS) technology applied in clinic. This consensus aimed to guide clinicians how to rationally apply the gene testing to know more comprehensive genetic testing information, and formulate more precise treatment strategies for patients with advanced breast cancer. [ABSTRACT FROM AUTHOR]

Breast cancer is the most common malignant tumor in women, of which early-stage (stages Ⅰ-Ⅱ) breast cancer (EBC) accounts for 73.1%. The strategy of postoperative adjuvant treatment relies mainly on the clinicopathologic characteristics of patients, but there are certain deficiencies in the assessment of treatment benefits and disease prognosis. Multigene testing tools can evaluate the prognosis and predict therapeutic effects of breast cancer patients to guide the clinical decision-making on whether to use adjuvant chemotherapy, radiotherapy, and endocrine therapy by detecting the expression levels of specific genes. The consensus-writing expert group, based on the characteristics, validation results, and accessibility of the multigene testing tools and combined with clinical practice, described the result interpretation and clinical application of OncotypeDx® (21-gene), MammaPrint® (70-gene), RecurIndex® (28-gene), and BreastCancerIndex® (BCI, 7-gene) for hormone receptor-positive and human epidermal growth factor receptor 2-negative EBC. The development and validation process of each tool was also briefly introduced. It is expected that the consensus will help to guide and standardize the clinical application of multigene testing tools and further improve the level of precise treatment for EBC. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Electric Power Automation Equipment / Dianli Zidonghua Shebei is the property of Electric Power Automation Equipment Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Breast cancer is one of the common malignant tumors of women. In recent years, the incidence of breast cancer is high. Human epidermal growth factor receptor-2 (HER-2) is a tyrosine kinase receptor. Breast cancer with abnormal amplification or overexpression of HER-2 have the characteristics of strong tumor invasiveness and poor prognosis. With the advent of anti-HER-2 drugs, the survival period of patients with HER-2 positive breast cancer is gradually prolonged, and the prognosis of patients with HER-2 positive breast cancer is improved. However, the efficacy of traditional HER-2 targeted drugs on patients with low expression of HER-2 is very limited, and the treatment of breast cancer with low expression of HER-2 is still facing challenges. This article reviews the standardization process of the American Society of Clinical Oncology and the American Society of Pathologists guidelines for HER-2 detection, and puts forward the data basis and possibility of defining a new subtype of breast cancer with low expression of HER-2. The birth of a new generation of HER-2 targeting drugs makes it possible to treat patients with low expression of HER-2, which will redefine breast cancer with low expression of HER-2 and provide a new opportunity for the prognosis of patients with low expression of HER-2. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Hormone receptor (HR), human epidermal growth factor receptor-2(HER-2) double positive breast cancer is a highly aggressive disease, and it is more susceptible to drug resistance and metastasis. Currently, although anti-HER-2 monoclonal antibody combined with endocrine therapy is commonly used in clinical practice, patients with HR-positive and HER-2-positive still have a poor prognosis. That may be caused by the activation of downstream PI3K/ Akt/ mTOR signaling pathway of HER-2. Therefore, simultaneously blocking the extracellular, intracellular and downstream PI3K/ Akt/ mTOR signaling pathway of HER-2, as well as the dual blockade of HER-2 and HR, is more conducive to the treatment of HR positive and HER-2 positive breast cancer. The small-molecule tyrosine kinase inhibitor neratinib not only inhibits the phosphorylation of HER-1, HER-2 and HER-4, but also blocks the downstream signal transduction of PI3K/ Akt and Ras/ Raf/ MEK/ ERK pathways. The intensive adjuvant chemotherapy studies has confirmed that nelatinib can improve the prognosis of patients with HER-2 positive breast cancer, especially those with HR and HER-2 double positive patients. Nelatinib has also achieved positive effect on the treatment of advanced breast cancer, but relevant data on the treatment of HR-positive and HER-2 positive advanced breast cancer are still lacking. Lapatinib, a small-molecule HER inhibitor similar to neratinib, has shown some effects on the treatment of HR-positive and HER-2 positive patients with advanced breast cancer. Given that nelatinib has a superior efficacy than lapatinib, it is expected to provide more ideas and options for the treatment strategies of breast cancer. [ABSTRACT FROM AUTHOR]

Breast cancer is the most common and fatal malignant tumor in women, which causes great social burden throughout the world. At present, chemotherapy is still the most important treatment manner of advanced breast cancer, and platinum drugs are one of the commonly used chemotherapeutic drugs. Based on the substantial evidence, the expert committee deeply discusses the clinical application of platinum drugs in advanced breast cancer, gives the reasonable suggestions for its clinical usage, effectiveness and adverse effects. This consensus aims to guide physicians to use drugs reasonably and standardize the diagnosis and treatment. [ABSTRACT FROM AUTHOR]

As a new type of anthracyclines, pegylated liposomal doxorubicin ( PLD) is widely used in the treatment of a variety of malignant tumors, including soft tissue sarcoma, ovarian cancer,breast cancer, multiple mycloma, and so on. Compared with traditional anthracydines, PLD can significantly decrease the incidences of adverse events such as cardiac toxicity and alopecia. However, the use of PLD will he accompanied with toxic side effects such as hand-foot syndrome, oral mucositis, and infusion reaction. This consensus will mainly focus on the mechanism, prevention and treatment of adverse events of PLD, in order In improve the therapeutic efficency of PLD and lifequality of patients. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To explore the associations between genetic variations of DNA repair gene RAD52 and response to platinum-based chemotherapy of small cell lung cancer (SCLC), and to analyze the influencing factors on survival. Methods Nine haplotype-tagging single nucleotide polymorphisms (htSNPs) of RAD52 were genotyped by Sequenom Mass ARRAY technology in 939 SCLC patients who received platinum-based chemotherapy, and had different response and survival time. The associations between genotypes and platinum-based chemotherapy response were analyzed by odds ratios (ORs) and 95%confidence intervals (CIs), adjusted for sex, age, smoking, KPS, staging and chemotherapy regimens, by unconditional logistic regression model. The relative ratios (RRs) were estimated using Cox proportional hazards regression model. Results Among the 939 cases, 483 (51. 4%) cases received cis-platinum and etoposide treatment while others treated with carboplatin and etoposide. Six hundred and eighty two patients were chemotherapy responders in the study with a response rate of 72.6%. Patients were followed up to get their survival information. The median survival time (MST) of these patients was 25 months. We found that rs10774474 SNP which located in the 5′-flanking region of RAD52 was significantly associated with chemotherapy response. Compared with the TT genotype, patients with TA and AA genotype had a worse chemotherapy response and increased risk of no-response (P=0. 004). Correlation analysis showed that patients with KPS >80 had a better chemotherapy response than those with KPS≤80 (P=0.001). The patients with extensive-stage had a worse chemotherapy response than those with limited-stage (P<0.001). Cox proportional hazards regression model analysis showed that nine htSNPs of RAD52 were not associated with the overall survival (OS) of SCLC patients who received platinum-based chemotherapy. Age≤56, KPS>80, limited-stage, chemotherapy response and radiation therapy can remarkably prolong OS (all P<0.05). Conclusions These results suggest that RAD52 genetic polymorphism rs10774474 plays an important role in the response to platinum-based chemotherapy, and may be a potential genetic biomarker for SCLC personalized treatment. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Ｔｏ ａｓｓｅｓｓ ｔｈｅ ｅｆｆｉｃａｃｙ ｏｆ ｖｉｎｏｒｅｌｂｉｎｅ （ＮＶＢ）⁃ｂａｓｅｄ ｒｅｇｉｍｅｎｓ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｍｅｔａｓｔａｔｉｃ ｔｒｉｐｌｅ ｎｅｇａｔｉｖｅ ｂｒｅａｓｔ ｃａｎｃｅｒ （ｍＴＮＢＣ） ｐｒｅｔｒｅａｔｅｄ ｗｉｔｈ ａｎｔｈｒａｃｙｃｌｉｎｅｓ ａｎｄ ｔａｘａｎｅｓ． Ｍｅｔｈｏｄｓ　Ｃｌｉｎｉｃａｌ ｄａｔａ ｏｆ ４８ ｐａｔｉｅｎｔｓ ｄｉａｇｎｏｓｅｄ ａｎｄ ｔｒｅａｔｅｄ ｆｏｒ ｍＴＮＢＣ ｂｅｔｗｅｅｎ ２００４ ａｎｄ ２０１２ ａｔ ｔｈｅ Ｃａｎｃｅｒ Ｈｏｓｐｉｔａｌ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ ｏｆ Ｍｅｄｉｃａｌ Ｓｃｉｅｎｃｅｓ （ＣＡＭＳ） ｗｅｒｅ ｒｅｔｒｏｓｐｅｃｔｉｖｅｌｙ ａｎａｌｙｚｅｄ． Ａｌｌ ｐａｔｉｅｎｔｓ ｗｅｒｅ ｐｒｅｔｒｅａｔｅｄ ｗｉｔｈ ａｎｔｈｒａｃｙｃｌｉｎｅｓ ａｎｄ ａｔ ｌｅａｓｔ ｏｎｅ ｔａｘａｎｅ ｉｎ ｎｅｏ⁃ａｄｊｕｖａｎｔ， ａｄｊｕｖａｎｔ ｏｒ ｃｈｅｍｏｔｈｅｒａｐｙ ｆｏｒ ｍＴＮＢＣ ａｎｄ ｐａｔｉｅｎｔｓ ｓｈｏｕｌｄ ｂｅ ｈａｖｉｎｇ ａｔ ｌｅａｓｔ ｏｎｅ ｍｅａｓｕｒａｂｌｅ ｍｅｔａｓｔａｔｉｃ ｌｅｓｉｏｎ． Ｔｏｔａｌｌｙ， ４８ ｐａｔｉｅｎｔｓ ｗｅｒｅ ｉｎｃｌｕｄｅｄ ｉｎ ｔｈｉｓ ｓｔｕｄｙ， ｏｆ ｗｈｉｃｈ ２１ ｃａｓｅｓ ｒｅｃｅｉｖｅｄ ｆｉｒｓｔ⁃ｌｉｎｅ ｃｈｅｍｏｔｈｅｒａｐｙ ａｎｄ ２７ ｃａｓｅｓ ｒｅｃｅｉｖｅｄ ｓｅｃｏｎｄ⁃ｌｉｎｅ ｃｈｅｍｏｔｈｅｒａｐｙ． Ｂａｓｅｄ ｏｎ ｔｈｅ ｒｅｇｉｍｅｎ ｔｈｅｙ ｒｅｃｅｉｖｅｄ， ２２ ｐａｔｉｅｎｔｓ ｗｅｒｅ ｔｒｅａｔｅｄ ｗｉｔｈ ＮＶＢ ｐｌｕｓ ｐｌａｔｉｎｕｍ （ＮＰ）， ａｎｄ ２６ ｐａｔｉｅｎｔｓ ｗｉｔｈ ＮＶＢ ｐｌｕｓ ｃａｐｅｃｉｔａｂｉｎｅ （ＮＸ）． Ｒｅｓｕｌｔｓ 　Ａｆｔｅｒ ７０ ｍｏｎｔｈｓ ｆｏｌｌｏｗ⁃ｕｐ， ｉｎ ｔｈｅ ｔｏｔａｌ ｇｒｏｕｐ ｏｆ ｐａｔｉｅｎｔｓ， ｔｈｅ ｏｂｊｅｃｔｉｖｅ ｒｅｓｐｏｎｓｅ ｒａｔｅ ｗａｓ ２０．８％， ｃｌｉｎｉｃａｌ ｂｅｎｅｆｉｔ ｒａｔｅ ｗａｓ ４３．８％， ｍｅｄｉａｎ ｐｒｏｇｒｅｓｓｉｏｎ ｆｒｅｅ ｓｕｒｖｉｖａｌ （ＰＦＳ） ｗａｓ ４．４ ｍｏｎｔｈｓ ａｎｄ ｍｅｄｉａｎ ｏｖｅｒａｌｌ ｓｕｒｖｉｖａｌ （ＯＳ） ｗａｓ １５．５ ｍｏｎｔｈｓ． Ｉｎ ａｄｄｉｔｉｏｎ， ｔｈｅ ＯＲＲ ｗａｓ ｓｉｇｎｉｆｉｃａｎｔｌｙ ｂｅｔｔｅｒ ｉｎ ｔｈｅ ＮＰ ａｒｍ ｖｅｒｓｕｓ ＮＸ ａｒｍ （３３．８％ ｖｓ．７．７％， Ｐ ＝ ０．０２９） ａｓ ｗｅｌｌ ａｓ ＰＦＳ ｗａｓ ｓｔａｔｉｓｔｉｃａｌｌｙ ｉｍｐｒｏｖｅｄ ｉｎ ｔｈｅ ＮＰ ａｒｍ ｔｈａｎ ＮＸ ａｒｍ （５．３ ｍ ｖｓ． ３．０ ｍ， Ｐ ＝０．０２３）． Ｓｉｍｉｌａｒ ｔｒｅｎｄ ｗａｓ ｏｂｓｅｒｖｅｄ ｉｎ ｔｈｅ ＯＳ， ａｌｔｈｏｕｇｈ ｔｈｅ ｄｉｆｆｅｒｅｎｃｅ ｗａｓ ｎｏｔ ｓｔａｔｉｓｔｉｃａｌｌｙ ｓｉｇｎｉｆｉｃａｎｔ （２７．７ ｍ ｖｓ． １４．８ ｍ， Ｐ ＝ ０．０７７）． Ｉｎ ａｌｌ， ｔｈｅ ｍｏｓｔ ｆｒｅｑｕｅｎｔｌｙ ｒｅｐｏｒｔｅｄ ａｄｖｅｒｓｅ ｅｖｅｎｔｓ ｗｅｒｅ Ｇ１／２ ｇａｓｔｒｏｉｎｔｅｓｔｉｎａｌ ｔｏｘｉｃｉｔｙ （６８．８％） ａｎｄ ｎｅｕｔｒｏｐｅｎｉａ （６２．５％） ． Ｎｏ ｓｉｇｎｉｆｉｃａｎｔ ｄｉｆｆｅｒｅｎｃｅ ｗａｓ ｏｂｓｅｒｖｅｄ ｂｅｔｗｅｅｎ ｔｈｅ ＮＰ ａｒｍ ａｎｄ ＮＸ ａｒｍ （Ｐ ＞ ０．０５）． Ｔｈｅ ｐｅｒｃｅｎｔａｇｅ ｏｆ ｐａｔｉｅｎｔｓ ｗｈｏ ｄｅｌａｙｅｄ ｃｈｅｍｏｔｈｅｒａｐｙ ａｄｍｉｎｉｓｔｒａｔｉｏｎ ｉｎ ｔｈｅ ＮＰ ａｒｍ ａｎｄ ＮＸ ａｒｍ ｗａｓ ９．１％ （ｎ ＝ ２）， ａｎｄ ３．８％ （ｎ ＝ １）， ｒｅｓｐｅｃｔｉｖｅｌｙ． Ｃｏｎｃｌｕｓｉｏｎｓ　ＮＶＢ⁃ｂａｓｅｄ ｃｏｍｂｉｎａｔｉｏｎ ｃｈｅｍｏｔｈｅｒａｐｙ ｄｅｍｏｎｓｔｒａｔｅｓ ｍｏｄｅｒａｔｅ ｅｆｆｉｃａｃｙ ｉｎ ｍＴＮＢＣ ｐａｔｉｅｎｔｓ ｐｒｅｔｒｅａｔｅｄ ｗｉｔｈ ａｎｔｈｒａｃｙｃｌｉｎｅｓ ａｎｄ ｏｎｅ ｔａｘａｎｅ ｗｉｔｈ ｍａｎａｇｅａｂｌｅ ｔｏｘｉｃｉｔｙ． ＮＰ ｒｅｇｉｍｅｎ ｓｈｏｗｓ ｐｏｔｅｎｔｉａｌ ｓｕｐｅｒｉｏｒｉｔｙ ｏｖｅｒ ＮＸ ｒｅｇｉｍｅｎ， ａｎｄ ｓｈｏｕｌｄ ｂｅ ｆｕｒｔｈｅｒ ｖｅｒｉｆｉｅｄ ｉｎ ｒａｎｄｏｍｉｚｅｄ ｐｈａｓｅ Ⅲ ｃｌｉｎｉｃａｌ ｔｒｉａｌ ｉｎ ｌａｒｇｅｒ ｃｏｈｏｒｔ． [ABSTRACT FROM AUTHOR]